Patents by Inventor Mark D. Wittman

Mark D. Wittman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20110124623
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: January 28, 2011
    Publication date: May 26, 2011
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7879855
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: March 26, 2009
    Date of Patent: February 1, 2011
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • TRIAZINE KINASE INHIBITORS
    Publication number: 20100197654
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents.
    Type: Application
    Filed: July 24, 2008
    Publication date: August 5, 2010
    Inventors: Upender Velaparthi, Peiying Liu, Mark D. Wittman, David R. Langley
  • THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100120770
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's disease.
    Type: Application
    Filed: April 9, 2008
    Publication date: May 13, 2010
    Inventors: Anne Marinier, Marco Dodier, Stephan Roy, Kurt Zimmermann, Xiaopeng Sang, Mark D. Wittman, David R. Langley, Ramkumar Rajamani
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20100113454
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anti-cancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: April 17, 2008
    Publication date: May 6, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Anthony J. Sampognaro, Mark D. Wittman
  • THIAZOLYL COMPOUNDS USEFUL AS KINASE INHIBITORS
    Publication number: 20100048581
    Abstract: The invention provides compounds of formula I [INSERT CHEMICAL STRUCTURE HERE] (I) and pharmaceutically acceptable salts thereof. The formula I thiazolyl compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 25, 2010
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Anne Marinier, Claude A. Quesnelle, Marco Dodier, Stephan Roy, Patrice Gill, Mark D. Wittman, David R. Langley
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20090239838
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: March 26, 2009
    Publication date: September 24, 2009
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Pyrrolotriazine kinase inhibitors
    Patent number: 7534792
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: May 19, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Tyrosine kinase inhibitors
    Patent number: 7470696
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Grant
    Filed: January 23, 2007
    Date of Patent: December 30, 2008
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • PYRROLOTRIAZINE KINASE INHIBITORS
    Publication number: 20080009497
    Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.
    Type: Application
    Filed: July 5, 2007
    Publication date: January 10, 2008
    Inventors: Mark D. Wittman, Harold Mastalerz, Kurt Zimmermann, Mark G. Saulnier, Upender Velaparthi, Dolatrai M. Vyas, Guifen Zhang, Walter Lewis Johnson, David B. Frennesson, Xiaopeng Sang, Peiying Liu, David R. Langley
  • Benzimidazole C-2 heterocycles as kinase inhibitors
    Patent number: 7312215
    Abstract: Benzimidazole derivatives having the general formula I are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.
    Type: Grant
    Filed: July 20, 2004
    Date of Patent: December 25, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Anne Marinier, Carl Ouellet, Stephan Roy, Mark D. Wittman
  • Tyrosine kinase inhibitors
    Patent number: 7232826
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes
    Type: Grant
    Filed: September 29, 2003
    Date of Patent: June 19, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Tyrosine kinase inhibitors
    Patent number: 7223757
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: May 29, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Tyrosine kinase inhibitors
    Patent number: 7189716
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
    Type: Grant
    Filed: January 5, 2004
    Date of Patent: March 13, 2007
    Assignee: Bristol-Myers Squibb Company
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • Tyrosine kinase inhibitors
    Patent number: 7081454
    Abstract: The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases which can be treated by inhibiting tyrosine kinase enzymes.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: July 25, 2006
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Novel tyrosine kinase inhibitors
    Publication number: 20040180897
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: January 5, 2004
    Publication date: September 16, 2004
    Inventors: Francis Beaulieu, Carl Ouellet, Kurt Zimmermann, Upender Velaparthi, Mark D. Wittman
  • Novel tyrosine kinase inhibitors
    Publication number: 20040092514
    Abstract: The present invention provides compounds of Formula I or II that are useful as anti-cancer agents and other diseases that can be treated by inhibiting tyrosine kinase enzymes.
    Type: Application
    Filed: September 29, 2003
    Publication date: May 13, 2004
    Inventors: Upender Velaparthi, Mark D. Wittman
  • Novel tyrosine kinase inhibitors
    Publication number: 20040044203
    Abstract: The present invention provides compounds of formula I 1
    Type: Application
    Filed: October 2, 2002
    Publication date: March 4, 2004
    Inventors: Mark D. Wittman, Neelakantan Balasubramanian, Upender Velaparthi, Kurt Zimmermann, Mark G. Saulnier, Peiying Liu, Xiaopeng Sang, David B. Frennesson, Karen M. Stoffan, James G. Tarrant, Anne Marinier, Stephan Roy
  • Phosphonooxymethyl ethers of taxane derivatives
    Patent number: 6455575
    Abstract: The present invention concerns antitumor compounds. More particularly, the invention provides novel taxane derivatives, pharmaceutical compositions thereof, and their use as antitumor agents.
    Type: Grant
    Filed: June 6, 1997
    Date of Patent: September 24, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jerzy Golik, Dolatrai Vyas, John J. Wright, Henry Wong, John F. Kadow, John K. Thottathil, Wen-Sen Li, Murray A. Kaplan, Robert K. Perrone, Mark D. Wittman
  • Taxane anticancer agents
    Patent number: 6362217
    Abstract: The present invention concerns novel 7-deoxy taxane derivatives their use as antitumor agents, and pharmaceutical formulations.
    Type: Grant
    Filed: March 8, 2001
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventors: John F. Kadow, Wendy S. Schwartz, Paul M. Scola, Qiufen May Xue, Mark D. Wittman, Mu-Jen Wu